The global polycystic ovary syndrome (PCOS) market is anticipated to grow at a modest CAGR of around 4.0% during the forecast period (2021-2027). PCOS is an endocrine disorder found in women of childbearing age (ages 15 to 44) which affects their hormone levels. Women with PCOS produce higher-than-normal amounts of male hormones. This hormone imbalance causes their body to skip menstrual periods and makes it harder for them to get pregnant. In PCOS women’s ovaries, the reproductive organs that produce estrogen and progesterone are affected majorly. Diuretics, Insulin Sensitizing Agents, Antiandrogens, and Oral Contraceptive Pills are some of the major drugs used in the diagnosis of PCOD disorder.
To Request a Sample of our Report on Polycystic Ovary Syndrome (PCOS) Market: https://www.omrglobal.com/request-sample/polycystic-ovary-syndrome-pcos-market
The changing lifestyles, rising obesity in women, and increasing cases of hormonal imbalances in women are the factors that contributed to the rise in the incidence of PCOS. According to the Centres for Disease Control and Prevention, approximately 5 million women of reproductive age suffer from the polycystic ovarian syndrome. Additionally, according to the International Journal of Reproduction, Contraception, Obstetrics, and Gynecology, a study was conducted on 170 women of reproductive age, in which 70 women were affected with PCOS which was 41%, in which 16% were married women and 24% in unmarried women with PCOS. Obesity in women is another major factor that increases the chances of PCOS. Thus, the high prevalence is accelerating market growth.
However, factors such as side effects coupled with PCOS drugs such as weight gain, unwanted hair growth, increase insulin resistance, cardiovascular risks, and thromboembolic events are hindering the growth of the market. Further, the advancements in PCOS is also accelerating the market growth, For instance, in February 2020, Ava, a digital healthcare company focused on women’s reproductive health, announced that it had received clearance approval from FDA for its Ava Fertility Tracker, a wearable fertility tracking sensor bracelet and accompanying app. The device aid women in ovulation prediction and facilitation of conception.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Drug Type
- By Diagnosis Type
- By Treatment Type
- By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Abbott Laboratories, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co., Ferring Pharmaceuticals, Merck & Co., Inc.., Novartis AG, Teva Pharmaceutical Industries Ltd., among others.
(Get 15% Discount on Buying this Report)
A full Report of Polycystic Ovary Syndrome (PCOS) Market is Available at: https://www.omrglobal.com/industry-reports/polycystic-ovary-syndrome-pcos-market
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global PCOS Market Report Segment
By Drug Type
- Diuretics
- Insulin Sensitizing Agents
- Antiandrogens
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Anti-Obesity
- Oral Contraceptive Pills
By Diagnosis Type
- Ultrasound
- Pelvic Exam
- Blood Test
- By Treatment Type
- Ovarian Wedge Resection
- Laparoscopic Ovarian Drilling
- Acupuncture
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies (Online and Offline)
- Fertility Clinics
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
